U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07277322) titled 'Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases' on Dec. 02.
Brief Summary: This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Cancer
Liver Metastases
Intervention:
DRUG: Dupilumab
Dupilumab is commercially sourced, and provided as 300mg pre-filled syringes, though packaging may vary. Dupilumab 600mg SC on Day 1 and 300mg SC on Day 15 (+/-2 days).
DRUG: Toripalimab...